Volume 20, Issue 12 (3-2018)
J Arak Uni Med Sci 2018, 20(12): 1-9 |
Back to browse issues page
Azadeh Agahi1 
, Gholamali Hamidi2 , Mahmoud Salami3 , Azam Alinaghipour1 , Reza Daneshvar Kakhaki4 , Masoud Soheili1
, Gholamali Hamidi2 , Mahmoud Salami3 , Azam Alinaghipour1 , Reza Daneshvar Kakhaki4 , Masoud Soheili1
1- Department of Medical Basic Sciences, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
2- PhD of Physiology, Department of Medical Basic Sciences, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran. ,hamiidi@yahoo.com
3- PhD of Physiology, Department of Medical Basic Sciences, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
4- Neurologist, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
2- PhD of Physiology, Department of Medical Basic Sciences, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran. ,
3- PhD of Physiology, Department of Medical Basic Sciences, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
4- Neurologist, Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Abstract: (5837 Views)
Abstract
Background: Alzheimer’s disease (AD) is a most common neurodegenerative disorder. The aim of this study was to investigate the effect of probiotic on cognitive function in patients with Alzheimer disease.
Materials and Methods: This clinical trial was conducted among 48 AD patients. The patients were randomly divided into two groups (n=23 in control group and n=25 in probiotic group) treating with capsules 500mg containing maltodextrine (control group) and probiotic supplementation (probiotic group) for 12 weeks. Mini-mental state examination (MMSE) and TYM test score was recorded in all subjects before and after treatment.
Results: After 12 weeks intervention, compared with the control group, the probiotic treated, patients with mild degree of Alzheimer disease showed an improvement in the MMSE, TYM score
(p < 0.0001).
Conclusion: Our current study demonstrated that probiotic consumption for 12 weeks positively affects cognitive function in mild degree of AD.
Background: Alzheimer’s disease (AD) is a most common neurodegenerative disorder. The aim of this study was to investigate the effect of probiotic on cognitive function in patients with Alzheimer disease.
Materials and Methods: This clinical trial was conducted among 48 AD patients. The patients were randomly divided into two groups (n=23 in control group and n=25 in probiotic group) treating with capsules 500mg containing maltodextrine (control group) and probiotic supplementation (probiotic group) for 12 weeks. Mini-mental state examination (MMSE) and TYM test score was recorded in all subjects before and after treatment.
Results: After 12 weeks intervention, compared with the control group, the probiotic treated, patients with mild degree of Alzheimer disease showed an improvement in the MMSE, TYM score
(p < 0.0001).
Conclusion: Our current study demonstrated that probiotic consumption for 12 weeks positively affects cognitive function in mild degree of AD.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2017/11/28 | Accepted: 2018/01/21
Received: 2017/11/28 | Accepted: 2018/01/21
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |